Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Antimicrob Agents Chemother
2000 Jun 01;446:1716-9. doi: 10.1128/AAC.44.6.1716-1719.2000.
Show Gene links
Show Anatomy links
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.
Giacometti A
,
Cirioni O
,
Del Prete MS
,
Barchiesi F
,
Fortuna M
,
Drenaggi D
,
Scalise G
.
???displayArticle.abstract???
The in vitro activities of buforin II, cecropin P1, and magainin II, alone and in combination with six clinically used antimicrobial agents, against 12 clinical isolates of Stenotrophomonas maltophilia were investigated. Antimicrobial activities were measured by MIC and time-kill studies. The isolates were susceptible to the peptides at concentrations in the range of 0.50 to 16 microg/ml. Synergy was observed when the peptides were combined with polymyxin E, meropenem, ceftazidime, piperacillin, and clarithromycin.
Alonso,
Multiple antibiotic resistance in Stenotrophomonas maltophilia.
1997, Pubmed
Alonso,
Multiple antibiotic resistance in Stenotrophomonas maltophilia.
1997,
Pubmed
Cannon,
Antimicrobial peptides. A family of wound healers.
,
Pubmed
,
Xenbase
Denton,
Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples.
1998,
Pubmed
Falla,
Mode of action of the antimicrobial peptide indolicidin.
1996,
Pubmed
George,
Multidrug resistance in enteric and other gram-negative bacteria.
1996,
Pubmed
Hanberger,
Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups.
1999,
Pubmed
Hancock,
Peptide antibiotics.
1999,
Pubmed
Hancock,
Antibacterial peptides and the outer membranes of gram-negative bacilli.
1997,
Pubmed
Hancock,
Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.
1998,
Pubmed
Howe,
Macrolides for the treatment of Pseudomonas aeruginosa infections?
1997,
Pubmed
Khardori,
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.
1990,
Pubmed
Molinari,
Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.
1993,
Pubmed
Moore,
Antimicrobial activity of cecropins.
1996,
Pubmed
Munter,
Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia.
1998,
Pubmed
Piers,
The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa.
1994,
Pubmed
Quinn,
Clinical problems posed by multiresistant nonfermenting gram-negative pathogens.
1998,
Pubmed
Vaara,
Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria.
1996,
Pubmed
Vartivarian,
A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.
1994,
Pubmed
Victor,
Xanthomonas maltophilia bacteremia in immunocompromised hematological patients.
1994,
Pubmed
Viljanen,
The outer membrane permeability-increasing action of deacylpolymyxins.
1991,
Pubmed
Yasuda,
Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin.
1993,
Pubmed
